Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13264542 | 0.86 | GAA (0.38) | GAACYP4F2CYP4A11CYP2C19KMT2A | |
| SCHEMBL31622729 | 0.83 | GAA (0.38) | GAACYP4F2CYP4A11KMT2ARXRA | |
| SCHEMBL20517453 | 0.82 | GAA (0.35) | GAACYP4F2CYP4A11CYP2C19ATR | |
| SCHEMBL21002088 | 0.81 | GAA (0.49) | GAACYP4F2CYP4A11CYP2C19KMT2A | |
| SCHEMBL25934709 | 0.79 | GAA (0.33) | GAACYP4F2CYP4A11RET | |
| SCHEMBL30758273 | 0.78 | GAA (0.44) | GAACYP4F2CYP4A11CYP2C19KMT2A | |
| SCHEMBL22236287 | 0.77 | GAA (0.36) | GAACYP4F2CYP4A11KMT2ARXRA | |
| SCHEMBL25934712 | 0.77 | GAA (0.34) | GAACYP4F2CYP4A11 | |
| SCHEMBL22826020 | 0.76 | GAA (0.33) | GAACYP4F2CYP4A11POLQ | |
| SCHEMBL1040373 | 0.76 | GAA (0.39) | GAACYP4F2CYP4A11CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986902-B1 | MACROCYCLIC INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-24 | — | — | EP | disclosed |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-27 | — | — | US | disclosed |
| US-20230021562-A1 | MACROCYLIC INDOLE DERIVATIVES MCL-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022251247-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022008674-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021099579-A1 | MACROCYCLIC INDOLE DERIVATIVES AS MCL-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | WO | disclosed |
| WO-2020254471-A1 | MACROCYCLIC INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021562-A1 | MACROCYLIC INDOLE DERIVATIVES MCL-1 INHIBITORS | MCL1, BCL2L1, BAK1 | GAA 3624/4885CYP4F2 4722/4885CYP4A11 4575/4885 |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BAK1, BCL2L1 | GAA 3823/4885CYP4F2 4338/4885CYP4A11 4239/4885 |
| US-20230130109-A1 | MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BCL2L1, BAK1 | GAA 3720/4885CYP4F2 4639/4885CYP4A11 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.